Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Clementia Pharmaceuticals Inc.
Headquarters: Montreal, QC, Canada
Website: N/A
Year Founded: 2011
Status: Acquired
BioCentury | Aug 17, 2023
Finance
Aug. 16 Quick Takes: CirCode follows Pfizer deal with JJDC-led series A
Plus: At last, approval Ipsen FOP therapy Sohono and updates from Compass Pathways, Day One-Sprint, Seagen, Artiva, Precision-Imugene, Impel
BioCentury | Oct 25, 2022
Regulation
Oct. 25 Quick Takes: FDA approves J&J’s Tecvayli, first bispecific T cell engager for MM
Plus: Novartis prunes programs and updates from Ipsen, Biogen, Astellas-Taysha, Alto, AZ and more
BioCentury | Oct 4, 2022
Data Byte
October’s advisory committee lineup
A three-day hearing will determine the fate of Makena
BioCentury | Aug 23, 2022
Regulation
Aug. 22 Quick Takes: European approval for Gilead’s twice-yearly HIV treatment
Plus EMA reviewing Travere’s sparsentan and Menarini’s elacestrant and updates from Pharvaris and more
BioCentury | Jun 30, 2022
Finance
June 29 Quick Takes: ReCode extends series B to $200M
Plus 89bio raises $94.5M and updates from Ipsen, Regeneron and more
BioCentury | Mar 8, 2022
Emerging Company Profile
Congruence: identifying protein folding correctors
Montreal-based newco is cataloging properties of misfolded proteins and building a virtual chemical library to screen for stabilizers
BioCentury | Feb 11, 2022
Deals
Feb. 10 Quick Takes: RA, Adjuvant ready Curevo to take on Shingrix with $60M A round
Seagen slides on guidance, and updates from Arkuda, Altesa, Aeglea, Congruence, 1859 and more
BioCentury | Aug 13, 2021
Regulation
Regulatory snag for palovarotene sinks Ipsen shares
Unresolved questions about data in Ipsen’s NDA for palovarotene have led the company to withdraw its application to FDA, delaying the approval process for what could be the first approved
BioCentury | Dec 12, 2020
Product Development
Ipsen is casting a wider BD net under new CEO Loew
French pharma to use $3B war chest to add clinical candidates, late-stage U.S. program
BioCentury | Nov 3, 2020
Management Tracks
Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more
Gene therapy developer Freeline Therapeutics Holdings plc (NASDAQ:FRLN) hired Mark Baldry as chief commercial officer. He previously held the same role at Wave Life Sciences Ltd. (NASDAQ:WVE).
Items per page:
1 - 10 of 50